Altimmune, Inc. announced Impairment loss on intangible asset of $12.4 million was recognized during the three months ended December 31, 2023 related to the acquired In-Process Research and Development asset associated with HepTcell. The overall response in the Phase 2 trial was deemed to be insufficient to warrant further advancement. As a result, any further development related to HepTcell has been stopped.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.39 USD | -6.34% | -16.97% | -34.31% |
May. 23 | Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM | |
May. 09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.31% | 559M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023